Arrhythmogenic Right Ventricular Dysplasia
13
5
6
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
Mayo AVC Registry and Biobank
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations
Clinical Cohort Study - TRUST
Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
South Asian Arrhythmogenic Cardiomyopathy Registry
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Multidisciplinary Study of Right Ventricular Dysplasia
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases